Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00631137 · ClinicalTrials.gov registry record · NA
Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma
A NA study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT00631137 is a NA study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 1 participants.
The verdict
NCT00631137, a NA study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
RATIONALE: Testosterone gel may be effective in preventing or lessening muscle weakness caused by steroid therapy in men receiving glucocorticoids for newly diagnosed high-grade glioma. PURPOSE: This randomized clinical trial is studying how well testosterone gel works in preventing weakness caused by steroid therapy in men receiving glucocorticoids for newly diagnosed high-grade glioma.
Interventions
- DRUG testosterone gel applied to skin
- DIETARY_SUPPLEMENT whey powder protein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00631137
The ClinicalTrials.gov registry entry for NCT00631137 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which testosterone gel applied to skin is the first listed.
NCT00631137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00631137 about?
NCT00631137 is a clinical study titled "Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma". RATIONALE: Testosterone gel may be effective in preventing or lessening muscle weakness caused by steroid therapy in men receiving glucocorticoids for newly diagnosed high-grade glioma. PURPOSE: This randomized clinical trial is studying how well testosterone gel works in preventing weakness caused...
What is the current status of trial NCT00631137?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2008-01. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00631137?
The interventions under investigation include: testosterone gel applied to skin (DRUG), whey powder protein (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00631137?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.